ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CAPR vs AVTX // NET PROFIT MARGIN

Capricor Therapeutics Inc. (NASDAQ) VS. Avalo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CAPR 2 — AVTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAPR VS. AVTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CAPR AVTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -18.86% -12.90% -5.96 AVTX /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.38 0.66 +2.72 CAPR /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.3 24.4 +17.90 CAPR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $370.9M $384.5M -$13.6M AVTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CAPR REV AVTX REV CAPR GROSS % AVTX GROSS % CAPR FCF AVTX FCF
FY 2025 $302.8M $59.0K — — -$72.7M -$51.5M
FY 2024 $22.3M $441.0K — — -$41.2M -$49.1M
FY 2023 $25.2M $1.9M — — -$25.6M -$30.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAPR // BETA —
AVTX // BETA —